Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 64 articles:
HTML format
Text format



Single Articles


    November 2018
  1. ERDMANN M, Sigler D, Uslu U, Gohl J, et al
    Risk Factors for Regional and Systemic Metastases in Patients with Sentinel Lymph Node-negative Melanoma.
    Anticancer Res. 2018;38:6571-6577.
    PubMed     Text format     Abstract available


  2. SUZUKI H, Takano G, Hanai N, Nishikawa D, et al
    Primary Tumor Size Predicts Distant Metastasis of Mucosal Malignant Melanoma in Head and Neck.
    Anticancer Res. 2018;38:6485-6490.
    PubMed     Text format     Abstract available


  3. MATTILA K, Raanta P, Lahtela V, Pyrhonen S, et al
    Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
    Anticancer Res. 2018;38:6393-6397.
    PubMed     Text format     Abstract available


  4. PAMIDIMUKKALA NV, Leonard MK, Snyder D, McCorkle JR, et al
    Metastasis Suppressor NME1 Directly Activates Transcription of the ALDOC Gene in Melanoma Cells.
    Anticancer Res. 2018;38:6059-6068.
    PubMed     Text format     Abstract available


    October 2018
  5. ORANGES CM, Sisti G, Nasioudis D, Tremp M, et al
    Hard Palate Melanoma: A Population-based Analysis of Epidemiology and Survival Outcomes.
    Anticancer Res. 2018;38:5811-5817.
    PubMed     Text format     Abstract available


    August 2018
  6. TRESKOVA I, Topolcan O, Windrichova J, Simanek V, et al
    OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma.
    Anticancer Res. 2018;38:4907-4911.
    PubMed     Text format     Abstract available


  7. PLANSKA D, Kovalska J, Cizkova J, Horak V, et al
    Tissue Rebuilding During Spontaneous Regression of Melanoma in the Melanoma-bearing Libechov Minipig.
    Anticancer Res. 2018;38:4629-4636.
    PubMed     Text format     Abstract available


    July 2018
  8. MOSCHOS MM, Dettoraki M, Androudi S, Kalogeropoulos D, et al
    The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
    Anticancer Res. 2018;38:3817-3824.
    PubMed     Text format     Abstract available


  9. ARIMOTO A, Yamashita K, Hasegawa H, Sugita Y, et al
    Immunosuppression Induced by Perioperative Peritonitis Promotes Lung Metastasis.
    Anticancer Res. 2018;38:4333-4338.
    PubMed     Text format     Abstract available


  10. TUPY R, Mirka H, Mracek J, Priban V, et al
    Tumor-related Perfusion Changes in White Matter Adjacent to Brain Tumors: Pharmacodynamic Analysis of Dynamic 3T Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:4149-4152.
    PubMed     Text format     Abstract available


    June 2018
  11. PIRLAMARLA AK, Tang J, Amin B, Kabarriti R, et al
    Vulvar Melanoma with Isolated Metastasis to the Extraocular Muscles: Case Report and Brief Literature Review.
    Anticancer Res. 2018;38:3763-3766.
    PubMed     Text format     Abstract available


  12. MANTAS D, Damaskos C, Garmpis N, Dimitroulis D, et al
    Abdominal Emergencies in Patients with Stage IV Melanoma: The Role of Surgery: A Single-centre Experience.
    Anticancer Res. 2018;38:3713-3718.
    PubMed     Text format     Abstract available


  13. SAKAMOTO A, Kato K, Hasegawa T, Ikeda S, et al
    An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells.
    Anticancer Res. 2018;38:3273-3282.
    PubMed     Text format     Abstract available


  14. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Text format     Abstract available


    May 2018
  15. MOSCHOS MM, Moustafa GA, Lavaris A, Damaskos C, et al
    Depression in Choroidal Melanoma Patients Treated with Proton Beam Radiotherapy.
    Anticancer Res. 2018;38:3055-3061.
    PubMed     Text format     Abstract available


  16. AL-QURAYSHI Z, Crowther JE, Hamner JB, Ducoin C, et al
    Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
    Anticancer Res. 2018;38:2897-2901.
    PubMed     Text format     Abstract available


    March 2018
  17. WALTER L, Heinzerling L
    BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Anticancer Res. 2018;38:1335-1341.
    PubMed     Text format     Abstract available


    February 2018
  18. BURGARD B, Schope J, Holzschuh I, Schiekofer C, et al
    Solarium Use and Risk for Malignant Melanoma: Meta-analysis and Evidence-based Medicine Systematic Review.
    Anticancer Res. 2018;38:1187-1199.
    PubMed     Text format     Abstract available


  19. GRECO M, Arcidiacono B, Chiefari E, Vitagliano T, et al
    HMGA1 and MMP-11 Are Overexpressed in Human Non-melanoma Skin Cancer.
    Anticancer Res. 2018;38:771-778.
    PubMed     Text format     Abstract available


  20. REICHRATH J, Lindqvist PG, DE Gruijl FR, Pilz S, et al
    A Critical Appraisal of the Recent Reports on Sunbeds from the European Commission's Scientific Committee on Health, Environmental and Emerging Risks and from the World Health Organization.
    Anticancer Res. 2018;38:1111-1120.
    PubMed     Text format     Abstract available


    January 2018

  21. Cutaneous Melanoma. 1st Edition. A Pocket Guide for Diagnosis and Management.
    Anticancer Res. 2018;38:587.
    PubMed     Text format    


    December 2017
  22. PONTI G, Manfredini M, Greco S, Pellacani G, et al
    BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.
    Anticancer Res. 2017;37:7043-7048.
    PubMed     Text format     Abstract available


  23. RAPI V, Dogan A, Schultheis B, Hartmann F, et al
    Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
    Anticancer Res. 2017;37:6911-6920.
    PubMed     Text format     Abstract available


  24. DELGADO AF, Delgado AF
    Complete Lymph Node Dissection in Melanoma: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:6825-6829.
    PubMed     Text format     Abstract available


  25. WOZNIAK M, Peczek L, Czernek L, Duchler M, et al
    Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions.
    Anticancer Res. 2017;37:6779-6789.
    PubMed     Text format     Abstract available


  26. YANAROJANA M, Nararatwanchai T, Thairat S, Tancharoen S, et al
    Antiproliferative Activity and Induction of Apoptosis in Human Melanoma Cells by Houttuynia cordata Thunb Extract.
    Anticancer Res. 2017;37:6619-6628.
    PubMed     Text format     Abstract available


  27. BERUS T, Halon A, Markiewicz A, Orlowska-Heitzman J, et al
    Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review.
    Anticancer Res. 2017;37:6541-6549.
    PubMed     Text format     Abstract available


    November 2017
  28. MA YS, Hsiao YT, Lin JJ, Liao CL, et al
    Phenethyl Isothiocyanate (PEITC) and Benzyl Isothiocyanate (BITC) Inhibit Human Melanoma A375.S2 Cell Migration and Invasion by Affecting MAPK Signaling Pathway In Vitro.
    Anticancer Res. 2017;37:6223-6234.
    PubMed     Text format     Abstract available


  29. NAJEM A, Krayem M, Perdrix A, Kerger J, et al
    New Drug Combination Strategies in Melanoma: Current Status and Future Directions.
    Anticancer Res. 2017;37:5941-5953.
    PubMed     Text format     Abstract available


    October 2017
  30. PSINAKIS F, Katseli A, Koutsandrea C, Frangia K, et al
    Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.
    Anticancer Res. 2017;37:5719-5726.
    PubMed     Text format     Abstract available


  31. HU WP, Kuo KK, Senadi GC, Chang LS, et al
    Photodynamic Therapy Using Indolines-Fused-Triazoles Induces Mitochondrial Apoptosis in Human Non-Melanoma BCC Cells.
    Anticancer Res. 2017;37:5499-5505.
    PubMed     Text format     Abstract available


  32. GARMPIS N, Damaskos C, Garmpi A, Dimitroulis D, et al
    Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Anticancer Res. 2017;37:5355-5362.
    PubMed     Text format     Abstract available


    September 2017
  33. USLU U, Schliep S, Schliep K, Erdmann M, et al
    Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Anticancer Res. 2017;37:5033-5037.
    PubMed     Text format     Abstract available


  34. SUCKOW MA, Wolter WR, Duffield GE
    The Impact of Environmental Light Intensity on Experimental Tumor Growth.
    Anticancer Res. 2017;37:4967-4971.
    PubMed     Text format     Abstract available


    August 2017
  35. KIM YJ, Song SY, Kim W, Jeong SY, et al
    Feasibility of Postoperative Radiotherapy Using Conventional Fractionation for Lymph Node Metastasis from Cutaneous Melanoma.
    Anticancer Res. 2017;37:4239-4246.
    PubMed     Text format     Abstract available


    July 2017
  36. USLU U, Schuler G, Breuninger H
    Factors Influencing Disease Progression in Patients with Head and Neck Melanoma.
    Anticancer Res. 2017;37:3811-3816.
    PubMed     Text format     Abstract available


  37. FURUDATE S, Fujimura T, Kambayashi Y, Kakizaki A, et al
    Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Anticancer Res. 2017;37:3461-3471.
    PubMed     Text format     Abstract available


  38. NATH K, Nelson DS, Roman J, Putt ME, et al
    Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
    Anticancer Res. 2017;37:3413-3421.
    PubMed     Text format     Abstract available


  39. TANAKA T, Fujita M, Hasegawa H, Arimoto A, et al
    Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence.
    Anticancer Res. 2017;37:3863-3869.
    PubMed     Text format     Abstract available


    June 2017
  40. USLU U, Erdmann M, Schliep S, Dorrie J, et al
    Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.
    Anticancer Res. 2017;37:3243-3248.
    PubMed     Text format     Abstract available


  41. JANIK ME, Szlezak D, Surman M, Golas A, et al
    Diversified beta-2-adrenergic Receptor Expression and Action in Melanoma Cells.
    Anticancer Res. 2017;37:3025-3033.
    PubMed     Text format     Abstract available


  42. LAUBE F, Glanz D
    Modulation of Melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based Signaling for TFRC Up-regulation in Human Melanoma Cells.
    Anticancer Res. 2017;37:3001-3007.
    PubMed     Text format     Abstract available


    April 2017
  43. YAMAUCHI K, Mitsunaga T, Afroze SH, Uddin MN, et al
    Structure-Activity Relationships of Methylquercetin on Anti-migration and Anti-proliferation Activity in B16 Melanoma Cells.
    Anticancer Res. 2017;37:1575-1579.
    PubMed     Text format     Abstract available


    March 2017

  44. Melanoma Development. Molecular Biology, Genetics and Clinical Application.
    Anticancer Res. 2017;37:1544.
    PubMed     Text format    


  45. YOSHIKAWA S, Kiyohara Y, Otsuka M, Kondou R, et al
    Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Anticancer Res. 2017;37:1321-1328.
    PubMed     Text format     Abstract available


  46. LAWSON BO, Khong HT
    Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
    Anticancer Res. 2017;37:1365-1368.
    PubMed     Text format     Abstract available


  47. SPILIOPOULOS K, Peschos D, Batistatou A, Ntountas I, et al
    Immunohistochemical Study of Vasculogenic Mimicry and Angiogenesis in Melanocytic Tumors of the Eye and the Periocular Area.
    Anticancer Res. 2017;37:1113-1120.
    PubMed     Text format     Abstract available


    February 2017
  48. RYU SH, Heo SH, Park EY, Choi KC, et al
    Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes.
    Anticancer Res. 2017;37:607-614.
    PubMed     Text format     Abstract available


    January 2017
  49. SEHMISCH L, Schild SE, Rades D
    Development of a Survival Score for Patients with Cerebral Metastases from Melanoma.
    Anticancer Res. 2017;37:249-252.
    PubMed     Text format     Abstract available


  50. FORTIS SP, Anastasopoulou EA, Voutsas IF, Baxevanis CN, et al
    Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
    Anticancer Res. 2017;37:143-148.
    PubMed     Text format     Abstract available


  51. NGUYEN AH, Detty SQ, Agrawal DK
    Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Anticancer Res. 2017;37:1-7.
    PubMed     Text format     Abstract available


    December 2016
  52. RADES D, Sehmisch L, Janssen S, Schild SE, et al
    Prognostic Factors After Whole-brain Radiotherapy Alone for Brain Metastases from Malignant Melanoma.
    Anticancer Res. 2016;36:6637-6640.
    PubMed     Text format     Abstract available


  53. NAFFOUJE SA, Naffouje R, Chen J, Salti GI, et al
    Validation and Enhancement of the Clinicopathological Melanoma Nomogram via Incorporation of a Molecular Marker in the Primary Tumor.
    Anticancer Res. 2016;36:6603-6610.
    PubMed     Text format     Abstract available


  54. SOLARI N, Gipponi M, Franco DS, Re F, et al
    Videoscopic Inguinal-iliac-obturator Lymph-node Dissection: New Videoscopic Technique for Regional Lymphadenectomy in Patients with Melanoma.
    Anticancer Res. 2016;36:6579-6583.
    PubMed     Text format     Abstract available


  55. YAN S, Holderness BM, Li Z, Seidel GD, et al
    Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.
    Anticancer Res. 2016;36:6449-6456.
    PubMed     Text format     Abstract available


  56. MANTSO T, Sfakianos AP, Atkinson A, Anestopoulos I, et al
    Development of a Novel Experimental In Vitro Model of Isothiocyanate-induced Apoptosis in Human Malignant Melanoma Cells.
    Anticancer Res. 2016;36:6303-6309.
    PubMed     Text format     Abstract available


    November 2016
  57. MARTON A, Kusz E, Kolozsi C, Tubak V, et al
    Vanillin Analogues o-Vanillin and 2,4,6-Trihydroxybenzaldehyde Inhibit NFkB Activation and Suppress Growth of A375 Human Melanoma.
    Anticancer Res. 2016;36:5743-5750.
    PubMed     Text format     Abstract available


    October 2016
  58. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


    September 2016
  59. BASNET A, Saad N, Benjamin S
    A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab.
    Anticancer Res. 2016;36:4795-8.
    PubMed     Text format     Abstract available


  60. DONIZY P, Biecek P, Halon A, Matkowski R, et al
    BILLCD8 - A Multivariable Survival Model as a Simple and Clinically Useful Prognostic Tool to Identify High-risk Cutaneous Melanoma Patients.
    Anticancer Res. 2016;36:4739-47.
    PubMed     Text format     Abstract available


  61. RAICA M, Jitariu AA, Cimpean AM
    Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma.
    Anticancer Res. 2016;36:4427-35.
    PubMed     Text format     Abstract available


    July 2016
  62. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Text format     Abstract available


  63. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Text format     Abstract available


    June 2016
  64. YAN S, Coffing BN, Li Z, Xie H, et al
    Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
    Anticancer Res. 2016;36:2871-80.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: